Externally applied medicine for treating skin disease and application thereof
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology for external use of drugs and skin diseases, applied in the field of biomedicine, can solve the problems of prolonged treatment time, drug resistance, strong side effects, etc., and achieve the effects of enhanced therapeutic effect, increased tolerance, and improved compliance
Active Publication Date: 2012-08-01
济南龙华医药技术有限公司
View PDF1 Cites 6 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0007] Although diflorasone, adapalene, and acitretin can be used for the treatment of various inflammatory skin diseases, large doses will have strong side effects on the human body, and long-term repeated use will also produce drug resistance, which will make the treatment of diseases difficult. Prolonged time is not beneficial to patients
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
[0024] Difluraxone and adapalene were crushed separately, dispersed evenly with liquid paraffin, and set aside. Heat and melt vaseline, lanolin, and stearic acid, and when cooled to 40°C-50°C, add diflurasone, adapalene, and liquid paraffin, stir evenly, and cool to obtain the product. Each gram of ointment contains 0.05 mg of diflurasone and 0.01 mg of adapalene.
[0027] Difluraxone and adapalene were crushed separately, dispersed evenly with liquid paraffin, and set aside. Heat and melt vaseline, lanolin, and stearic acid, and when cooled to 40°C-50°C, add diflurasone, adapalene, and liquid paraffin, stir evenly, and cool to obtain the product. Each gram of ointment contains 0.1 mg of diflurasone and 0.5 mg of adapalene.
[0030] Diflorathone and adapalene were crushed separately, dispersed evenly with liquid paraffin and simethicone oil, and set aside. Heat and melt vaseline, solid paraffin, lanolin, and stearic acid, and when cooled to 40°C-50°C, add diflurasone, adapalene, liquid paraffin, and simethicone, stir evenly, and cool, that is have to. Each gram of ointment contains 0.25 mg of diflurasone and 2.5 mg of adapalene.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention discloses an externally applied medicine for treating skin disease and application thereof. The medicine consists of an active ingredient and pharmaceutically acceptable auxiliary materials, wherein the active ingredient is a mixture of diflorasone and adapalene, or a mixture of diflorasone and acitretin, or a mixture of diflorasone, adapalene and acitretin. The invention overcomes the defects of poor treatment effect and high side effect of single medication, and the diflorasone and the adapalene or/and the acitretin are compounded to form the compound externally applied medicine. The preparation can be prepared into externally applied formulations in different forms; and due to synergic and complementary effects of medicines, the compound externally applied medicine has high treatment effect, lightens the adverse reaction of the patient in clinical application, has an obvious treatment effect on skin disease, and is easily accepted by the patient.
Description
technical field [0001] The invention relates to a medicine for external use for treating skin diseases and its application, in particular to a compound medicine for external use containing diflorasone and adapalene or / and acitretin and its application, belonging to the technical field of biomedicine. Background technique [0002] Dermatosis is a disease related to the skin, and is one of common diseases and frequently-occurring diseases that have a strong impact on people's health, and it has multiple types. [0003] Allergic skin diseases are skin diseases caused by allergens. Specific allergens can be divided into four categories: contact allergens, inhalation allergens, ingestion allergens, and injection allergens. Eczema is a common inflammatory skin disease of the epidermis and superficial dermis caused by various internal and external factors. Allergic dermatitis is a skin disease caused by allergens. It mainly refers to skin symptoms such as redness, swelling, itchin...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more